Scientists Develop World's Smallest Drug Deliverer
News Apr 12, 2013
This new and improved nanoscale courier may help light up cancer cells and provide a new patient-friendly, viable option to battle cancer.
“No one has ever made a one-pore, super-small silica particle – at 10 nanometers and below – to deliver medicine,” says Ulrich Wiesner, Cornell’s Spencer T. Olin Professor of Materials Science and Engineering. “Clearing this object out of the body quickly also minimizes its impact on the body.”
Wiesner presented the talk, “Cornell Dots: Fluorescent Core-shell Silica Nanoparticles to Interrogate Biological Environments,” at the American Chemical Society meeting in New Orleans on April 7.
Previously, Wiesner and his colleagues had demonstrated the useful, diagnostic aspects of C-Dots. Now, they have illustrated the porous C-Dots (mC-Dots, for mesoporous) concept: The mC-Dots could act like tiny Navy Seals on a seek-and-destroy mission: Find the tumor, deliver medicine to kill it, then escape in urine within a couple of hours.
A single C-Dot consists of dye molecules encased in a chemically inert silica shell that can be as small as 5 nanometers in diameter. (A nanometer is one-billionth of a meter, about three times the diameter of a silicon atom).
Previous research showed that the outside of the shell can be coated with organic molecules that will attach to such desired targets as tumor surfaces or even locations within tumors.
The cluster of dye molecules in a single dot in solution fluoresces near-infrared light much more brightly than single dye molecules, and the fluorescence will identify malignant cells, showing a surgeon exactly what needs to be cut out and helping ensure that all malignant cells are found. But, surgeons may one day forego the scalpel, because with a built-in pore, the mC-Dots have the ability to bring medicine to the tumor.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
UK Not Ready for Brexit’s Impact on Food, Report WarnsNews
Severe problems with the UK food system are likely unless issues are addressed, according to latest expert reportREAD MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018